Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 2 sources · 21 days · First seen · Last updated
AI drug discovery startup funding
Overview
The biotechnology and medical AI sectors have seen significant investment in platforms designed to accelerate drug discovery through artificial intelligence.
In late October 2026, the biotechnology spin-off ALLOX secured $10.5 million in seed funding to expand its platform, which integrates high-throughput genetics and AI to target difficult biological areas like protein-protein interactions. Following this, in November 2026, Boltz PBC raised $110 million in Series A funding to advance its biomolecular modeling and protein design technology, specifically aiming to streamline small molecule research by using AI models to identify promising candidates.
Entities
BoltzMol-1 · Júlia Domingo · Asabys Partners · Boltz PBC · Latham & Watkins
Timeline
-
[TECHNOLOGY] 2 sourcesBoltz raises $110 million for medical AI drug discovery
Medical AI startup Boltz has raised $110 million in Series A funding, led by Bessemer Venture Partners, to advance its BoltzMol-1 model for accelerating small molecule drug discovery.
-
[BUSINESS] 4 sourcesALLOX secures $10.5 million in seed funding for drug discovery platform
Biotech company ALLOX has raised $10.5 million in seed funding to scale its AI and genetics-driven platform for discovering new small-molecule drug targets.
Sources
legaldesire.com · siliconangle.com